In addition sale of the company, licensing or sale of any pharmaceutical product would apply.

We are still a long way off from sale of any pharmaceutical product since BETonMACE won't be done for a long time, and then you have drug applications in US and Europe, etc. Plus any new compound other than RVX-208 is going to have to start from scratch in Phase 1. So we are still years off from sale of a pharmaceutical product.

However, my understanding is that licensing of a product that falls outside of the ApoAI therapeutic field would be something not currenlty included in the RSP arrangement that would be included in the RSP arrangement subsequent to the amendment.